AbbVie Ends Partnership With BioArctic in Parkinson’s Disease
Summary : AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement…
Summary : AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement…
Summary : Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the companies have submitted an application to the U.S. Food…
Summary : AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at…
Summary : Chicago-based AbbVie has been making major decisions with company-wide impacts. The therapeutic company appears to be making changes that will…
Summary : Moderna is poised to begin Phase III of its pivotal clinical trial for its candidate vaccine for respiratory syncytial virus…
Summary : At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business,…
Summary : A nationwide study from the U.S. Centers for Disease Control and Prevention (CDC) is the first to show that immunity…
Synopsis : Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today…
Synopsis- Zydus announced today that it has received permission to initiate the Phase II (a) clinical study of its NLRP3 inhibitor “ZYIL1”…
Summary – U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate NUV-422. It is a…